He has published numerous papers on topics such as aspirin for primary prevention in low-risk individuals and the effects of pharmaceutical samples on physician prescribing behavior.

No abstract

No abstract

While aminosalicylates are recommended as first-line treatment for the reduction of symptoms and the prevention of relapse in patients with mild-to-moderate UC, many available formulations require patients to take multiple tablets or capsules two to four times daily, which may affect adherence. New dosage regimens and delivery systems have been developed or are under development to improve convenience of dosing and potentially improve adherence.